Using CT Angiography to Categorize & Stratify Risk in Patients with Subclinical to Unstable Coronary Artery Disease
Gregg Stone, MD; Ron Blankstein, MD; Renu Virmani, MD; Joe Schoepf, MD; Tony Das, MD
Using CT Angiography to Categorize & Stratify Risk in Patients with Subclinical to Unstable Coronary Artery Disease
Gregg Stone, MD; Ron Blankstein, MD; Renu Virmani, MD; Joe Schoepf, MD; Tony Das, MD
Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular...
Computed tomography angiography (CTA) has been increasingly used in the diagnosis of vascular disease and its a modality that offers many potential clinical benefits. The question is, how to actualize that benefit and get the most our of the modality. Elucid has developed an artificial intelligence software that might just answer that question.
Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular...
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular...
BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque...